Replies to post #109449 on Biotech Values

[DewDiligence]

Last month Roche said they are moving forward with an INFORM-SVR study (RG7227 with ritonavir boosting), which should start Q1/11. What's the point of Roche mentioning INFORM-SVR if in fact INFORM is completely dead?

Since then, Roche announced a major restructuring, which includes pruning some clinical programs. RG7227/INFORM is probably one of the programs being pruned, IMO.